BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years
Year: 2026
Type: article
Study design: Observational Study
Abstract: In a test-negative case-control design among children aged 6 months-4 years (n = 11 878) and 5-17 years (n = 16 687) in Kaiser Permanente Southern California, BNT162b2 2024-2025 effectiveness against hospitalization/emergency department/urgent care/outpatient was 36% (95% CI, -5% to 61%) and 42% (-2% to 67%), respectively suggesting pediatric COVID-19 vaccination remains beneficial.
Institutions: Kaiser Permanente, Pfizer (United States)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,752
Funder: Pfizer
OpenAlex ID: W7149370997